Orlynvah Tablet, Film Coated
Product Images NDC 81153-100

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Orlynvah (NDC 81153-100). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Iterum Therapeutics Us Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Sulopenem Etzadroxil And Probenecid 01)

Chemical structure of sulopenem etzadroxil and probenecid, showing molecular bonds and key functional groups consistent with the active ingredients' chemical formula C19H27NO7S3.*

FDA Label Image

Figure 2 (Sulopenem Etzadroxil And Probenecid 02)

Chemical structure diagram of the active ingredient sulopenem etzadroxil, showing its molecular bonds and configuration with the chemical formula C13H19NO4S.*

FDA Label Image

Ndc 81153-100-01rx Onlyorlynvah™(sulopenem Etzadroxiland Probenecid) Tablets500 mg/500 mg10 Tablets (Sulopenem Etzadroxil And Probenecid 03)

Packaging label for Orlynvah tablets containing sulopenem etzadroxil and probenecid 500 mg/500 mg. The label shows the film-coated oral tablets with a package count of 10 tablets. It includes storage instructions and manufacturer information for Iterum Therapeutics US Limited, Chicago, IL. The design features the product name and strength prominently in pink text with branding elements.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.